Sulforadex®: a stabilised synthetic sulforaphane
In a significant technical breakthrough, a synthetic sulforaphane has been successfully stabilised in a proprietary pharmaceutical composition, extending shelf life from days to years in open air and at ambient temperature.
This novel sulforaphane-cyclodextrin complex, called Sulforadex®, is stable, orally bioavailable and has attractive cost of goods. Most importantly, Sulforadex® represents a pharmaceutical development proposition with an atypical risk profile due to the pre-existing scientific evidence relating to both the safety and efficacy of its unstable counterpart.
The anti-cancer activity of sulforaphane was first discovered in 1992. There are now over 900 peer-reviewed scientific publications regarding the biological effects of sulforaphane; with over half of these dedicated to oncology.The mechanism of action is now largely understood to be anchored around the epigenetic regulation of the Nrf-2 pathway that drives the expression of antoxidant and detoxification genes. Furthermore, sulforaphane has been implicated with targets associated specifically with cancer stem cells (e.g. through the modulation of the Sonic hedgehog-GLI and the Wnt/ß-Catenin signalling pathway).